Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Geneva Claims Fluoxetine 10 Mg Cap Exclusivity; Barr Restates Cipro Income

  • News

Executive Summary

Geneva is reclaiming sole rights to the generic exclusivity for the 10 mg capsule form of fluoxetine.

You may also be interested in...



Pfizer Estrostep Fe Is Barr's Next Patent Challenge; Ortho-Novum Trial By Oct.

Barr's patent challenge against Pfizer's Estrostep Fe is the generic company's latest step in attempting to expand its oral contraceptives franchise.

Pfizer Estrostep Fe Is Barr's Next Patent Challenge; Ortho-Novum Trial By Oct.

Barr's patent challenge against Pfizer's Estrostep Fe is the generic company's latest step in attempting to expand its oral contraceptives franchise.

Medicare Rx Benefit "More Significant" Than Waxman/Hatch Reform - Barr

Enactment of a Medicare prescription drug benefit is a higher priority for generic drug companies than reforms to the Waxman/Hatch Act, Barr CEO Bruce Downey told analysts Aug. 7.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS037793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By